---
title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294363676.md"
description: "In Thursday's pre-market session, healthcare stocks showed significant volatility. Gainers included Nuwellis (up 119%), GlucoTrack (+47.36%), and Corcept Therapeutics (+19.93%). Conversely, Capricor Therapeutics plummeted 56%, while Inovio Pharmaceuticals (-21.31%) and Teladoc Health (-20.16%) also declined sharply. Several moves were attributed to recent Q2 earnings releases."
datetime: "2026-07-30T12:06:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294363676.md)
  - [en](https://longbridge.com/en/news/294363676.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294363676.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's Pre-Market Session

### Gainers

-   **Nuwellis** (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.
-   **GlucoTrack** (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding shares is at $1.8 million.
-   **China SXT Pharmaceuticals** (NASDAQ:SXTC) stock rose 46.28% to $0.08. The company's market cap stands at $2.0 million.
-   **Corcept Therapeutics** (NASDAQ:CORT) stock moved upwards by 19.93% to $111.48. The market value of their outstanding shares is at $9.9 billion. As per the press release, Q2 earnings came out yesterday.
-   **Mobile-health Network** (NASDAQ:MNDR) stock moved upwards by 15.86% to $1.68. The company's market cap stands at $1.7 million.
-   **SL Science Holding** (NASDAQ:SLBT) stock moved upwards by 15.38% to $3.0. The company's market cap stands at $1.4 billion.

### Losers

-   **Capricor Therapeutics** (NASDAQ:CAPR) stock fell 56.0% to $2.89 during Thursday's pre-market session.
-   **Inovio Pharmaceuticals** (NASDAQ:INO) shares fell 21.31% to $0.82. The company's market cap stands at $85.5 million.
-   **Teladoc Health** (NYSE:TDOC) shares fell 20.16% to $7.33. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q2 earnings came out yesterday.
-   **Pharming** (NASDAQ:PHAR) shares declined by 16.74% to $10.0. The company's market cap stands at $848.2 million. As per the press release, Q2 earnings came out today.
-   **Biomerica** (NASDAQ:BMRA) shares declined by 14.47% to $1.36. The market value of their outstanding shares is at $4.9 million.
-   **Advanced Biomed** (NASDAQ:ADVB) stock decreased by 13.94% to $9.45. The market value of their outstanding shares is at $17.9 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)
- [INO.US](https://longbridge.com/en/quote/INO.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)
- [CORT.US](https://longbridge.com/en/quote/CORT.US.md)
- [NUWE.US](https://longbridge.com/en/quote/NUWE.US.md)
- [TDOC.US](https://longbridge.com/en/quote/TDOC.US.md)
- [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md)
- [MNDR.US](https://longbridge.com/en/quote/MNDR.US.md)
- [SLBT.US](https://longbridge.com/en/quote/SLBT.US.md)
- [PHAR.US](https://longbridge.com/en/quote/PHAR.US.md)
- [BMRA.US](https://longbridge.com/en/quote/BMRA.US.md)
- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)

## Related News & Research

- [GlucoTrack Settles Disputed Debt with Convertible Note](https://longbridge.com/en/news/298511271.md)
- [Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP](https://longbridge.com/en/news/298582369.md)
- [GlucoTrack unit Lōkahi Therapeutics expands ai² platform into three divisions](https://longbridge.com/en/news/298326260.md)
- [Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions | GCTK Stock News](https://longbridge.com/en/news/298328118.md)
- [GlucoTrack issues $2 million 5% convertible note to Alto Opportunity Master Fund in settlement deal](https://longbridge.com/en/news/298504304.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**